NDAORALCAPSULE, TABLET, TABLETPriority Review
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOQUEZNA TRIPLE PAK is a fixed-dose combination oral therapy containing vonoprazan fumarate (a potassium-competitive acid blocker), amoxicillin, and clarithromycin for the eradication of Helicobacter pylori infection. It represents a novel triple therapy approach to treat H. pylori-associated conditions including peptic ulcer disease. The combination mechanism relies on acid suppression plus dual antibiotic coverage to achieve bacterial eradication.
Peak4.1 years to LOE
Product is in peak commercial phase with established market presence; commercial teams are likely focused on market penetration and maintaining formulary access against high competitive pressure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on VOQUEZNA TRIPLE PAK at Phathom Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.